PRAME is a target expressed in more than 50 cancers, including melanoma, lung, ovarian, breast, and endometrial cancer, among many others. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. To do so safely and effectively requires deep expertise in immunology, drug development and beyond.
Immatics has the broadest PRAME franchise with the most indications and therapeutic modalities.
Clinical trials
Immatics is evaluating its targeted PRAME cell therapies and bispecific product candidates and actively enrolling patients in ongoing clinical trials.
Press releases
Follow our progress as we advance PRAME therapies from lab to clinic and beyond.
Today we announced our full year financial results and provided a business update.
It’s the 40th anniversary meeting of the SITC conference and our Immatics colleagues are onsite!
We give thanks for our global teams, our progress and the patients and their families who remind us why our work matters.